Navigation Links
BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
Date:2/25/2009

MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. announced today that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available. The data, that once again confirms the excellent safety and efficacy results previously reported, will be presented at the 2009 Genitourinary Cancers Symposium (GU) on February 26-28, 2009 in Orlando, Florida.

Abstracts from three different studies, where PROSTVAC(TM) has been evaluated as monotherapy or in combination with other therapies, are presented at the conference. The results from the studies support the further investigation in patients suffering from advanced prostate cancer.

The abstracts can be seen in full at ASCO's website: http://www.asco.org.

Study I (Abstract no. 108)

Study title: "A Phase II study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF in Patients with PSA Progression After Local Therapy for Prostate Cancer."

In a study run by the Eastern Cooperative Oncology Group, the effect of PROSTVAC(TM) vaccination in patients with early stage recurrent prostate cancer was evaluated.

Results from the study demonstrate that by using PROSTVAC(TM) in an earlier disease setting, the vaccine has the ability to decrease the rate of rise in PSA levels indicating a potential delay in disease progression. In addition, the vaccine can be safely administered in a patient population with early stage prostate cancer.

Study II (Abstract no. 210)

Study title: "Comparing the Overall Survival of Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel, a Vaccine Admixed with one Costimulatory Molecule, and a Vaccine with Three Costimulatory Molecules."

In this National Cancer Institute (NCI) conducted study comparing the overall survival in patients with advanced prostate cancer, where patients were treated with chemotherapy (docetaxel), chemotherapy in combination with a pox-based vaccine, or PROSTVAC(TM). The study compared the predicted overall survival (as determined by the Halabi score), with the observed overall survival. The patient groups receiving vaccine therapy had improvements in overall survival versus what was predicted, by approximately 6 and 9 months. The group receiving PROSTVAC(TM) had an improvement in overall survival consistent with the previously reported efficacy data.

Study III (Abstract no. 184)

Study title: "Phase I Trial of Targeted Therapy with PSA-TRICOM Vaccine (V) and Ipilimumab (ipi) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)."

This NCI conducted study in patients with advanced prostate cancer evaluated a combination of PROSTVAC(TM) vaccination with an anti-CTLA4 antibody (Ipilimumab, provided under an National Cancer Institute Clinical Trials Agreement with Bristol-Myers Squibb, Inc.) The study confirms activity of this regimen on PSA responses in advanced disease patients, and was associated with manageable side effects. No > grade 2 adverse events were attributed to vaccine.

Further detailed results on PROSTVAC(TM) will be presented at the 2009 ASCO Annual Meeting on May 29 -June 2, 2009 in Orlando, Florida.

Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics, said: "We are proud that for the first time since obtaining an exclusive license from the NIH, detailed study results with PROSTVAC(TM) are being presented at a major conference. These data, although early stage, confirms the unique profile of our leading cancer vaccine candidate, ready for Phase III. We are looking forward to present further detailed PROSTVAC(TM) data throughout 2009."

Located in Mountain View, California, BN ImmunoTherapeutics is a subsidiary of Bavarian Nordic, headquartered in Denmark.

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology, MVA-BN(R), has been demonstrated in clinical trials to be one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX NASDAQ under the symbol BAVA.

For more information, please visit: www.bavarian-nordic.com

"Safe Harbour" Statement under the Private Securities Litigation Reform Act of 1995:

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic's periodic reports, if any, which we incorporate by reference.


'/>"/>
SOURCE BN ImmunoTherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
2. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
6. iCardiac Reports Significant Revenue Growth and Profitability
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
9. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
10. New Study Reports Improved Patient Outcomes for Breast Cancer Patients
11. Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the ... in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 Nobel ... three scientists, Jacques Dubochet, Joachim Frank ... in cryo-electron microscopy (cryo-EM) have helped ... the structural biology community. The winners worked with ... now routinely produce highly resolved, three-dimensional images of ...
(Date:10/5/2017)... YORBA LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is giving back to cancer ... shirt sold in October. , Now through October 31, shoppers can use promo ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):